---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-047856"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T13:56:09.625550+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tvardi completes merger with Cara, switches auditor to Deloitte, cash into 2H 2026

## Summary
- Completed merger with Cara Therapeutics; received ~$23.8M net cash; cash runway expected into 2H 2026.
- Dismissed Ernst & Young as auditor; engaged Deloitte & Touche for FY 2025; no disagreements reported.
- Phase 2 data for TTI-101 in IPF expected 2H 2025; IND for TTI-109 planned 1H 2025.
- Phase 1 study of TTI-101 in advanced solid tumors published in Clinical Cancer Research.

## SEC filing metadata
- accession: 0001104659-25-047856
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/0001104659-25-047856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/tm2514879d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-047856
- JSON: https://secwatch.observer/filing/0001104659-25-047856.json
- Plain text: https://secwatch.observer/filing/0001104659-25-047856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.